- RECCE® 327 Topical Gel (R327G) was demonstrated to be safe and well-tolerated in patients – R327G demonstrating highly encouraging efficacy results as determined by non-Data Safety Monitoring Board
- All patients completing treatment with R327G met the primary endpoint of complete cure or improvement, seen as early as 7 days
- No Serious Adverse Events noted in patients - recommendation for clinical trial to continue, reflecting promising potential of R327G as a safe and effective treatment for acute bacterial skin and skin structure infections, including diabetic foot infections
SYDNEY, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced that an independent non-Data Safety Monitoring Board (non-DSMB) has completed its review of safety and efficacy data from the Company’s ongoing Phase II clinical trial of its lead compound, RECCE® 327 Gel (R327G), in patients with acute bacterial skin and skin structure infections (ABSSSI), including diabetic foot infections (DFI).
"We're seeing some very promising results from the interim data in the Phase II trial, which confirm the safety and potential efficacy of R327G in treating ABSSSI, including diabetic foot infections”, said Professor Eugene Athan, Coordinating Principal Investigator of the study.
James Graham, Chief Executive Officer of Recce Pharmaceuticals, added, “We are extremely encouraged by the feedback from the non-Data Safety Monitoring Board and the profile of R327G. The absence of serious adverse events, coupled with the wide range of broad-spectrum efficacy across challenging wound infections, reinforces the potential of R327G to address unmet medical needs in the treatment of serious bacterial infections.”
The non-DSMB found no safety concerns and unanimously recommended continuing the clinical trial, which is expected to be completed by the end of the year. This decision was based on R327G’s excellent safety profile, with no serious adverse events (SAE) observed in patients and highly encouraging efficacy results.
The majority of patients treated with R327G demonstrated highly encouraging efficacy results, with all patients meeting the primary endpoint and achieving either complete cure or improvement, in some cases in as little as 7 days. These outcomes were measured using the Lipsky Clinical Resolution of Infection Scale (Lipsky Scale), a widely recognized tool for assessing the resolution of infections, particularly in diabetic foot infections. The non-DSMB's positive findings further underscore the strong safety profile of Recce’s innovative anti-infective therapy.
The conditions treated included diabetic foot ulcer, eczema, scratches, and puncture wound infections. A wide variety of infecting bacteria (Gram positive and Gram negative) were isolated and successfully treated with improvement/cure of infection in all patients that continued with their treatment.
| Patient ID | Age/Gender | Infection | Clinical Response |
| Patient 1 | 88/Male | ABSSSI | Cure (Day 7) |
| Patient 2 | 53/Male | ABSSSI | Cure (Day 7) |
| Patient 3 | 49/Male | ABSSSI | Cure (Day 7) |
| Patient 4 | 63/Female | ABSSSI | Cure (Day 7) |
| Patient 5 | 46/Male | ABSSSI | Cure (Day 14) |
| Patient 6 | 63/Female | ABSSSI | Cure (Day 14) |
| Patient 7 | 67/Male | ABSSSI | Improvement (Day 7) |
| Patient 8 | 72/Male | ABSSSI | Improvement (Day 7) |
| Patient 9 | 70/Male | ABSSSI | Improvement (Day 7) |
| Patient 10 | 59/Male | ABSSSI | Improvement (Day 7) |
| Patient 11 | 63/Male | ABSSSI | Improvement (Day 7) |
| Patient 12 | 68/Male | ABSSSI | Improvement (Day 14) |
| Patient 13 | 81/Female | ABSSSI | Withdrawn* |
| Patient 14 | 84/Female | ABSSSI | Improvement (Day 14) |
*While no serious adverse events were noted, one patient was discontinued due to pain at the wound site, which was judged to be unlikely related to R327G.
The Global ABSSSI treatment market size was valued at $7.3B USD in 2018 and is projected to reach $26B USD by 2032, representing a CAGR of 9.5% between 2019 and 2032.
The title of the Phase II clinical trial is an “Open-label, Pilot Efficacy Study and Exploratory Evaluation of the Systemic Bioavailability of Single and/or Multiple Doses of R327 as a Topical Gel Applied to Acute Bacterial Skin and Skin Structure Infections” (Trial ID ACTRN12624000973516) and is designed to evaluate the efficacy and systemic absorption of R327G when applied directly to the infected area.
More information on this trial can be found at the Australia New Zealand Clinical Trial Registry under the trial ID ACTRN12624000973516.
About Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.
Recce’s anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce’s anti-infectives have the potential to overcome the processes utilized by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.
The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognizing Recce’s efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts’ Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.
Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce’s anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.
Corporate Contact
James Graham
Recce Pharmaceuticals Ltd
+61 (02) 9256 2571
James.graham@recce.com.au
Media & Investor Relations (AU)
Andrew Geddes
CityPR
+61 (02) 9267 4511
ageddes@citypublicrelations.com.au
Media (USA)
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com
Investor Relations (USA & EU)
Guillame van Renterghem
LifeSci Advisors
gvanrenterghem@lifesciadvisors.com
Comments